Do you want to read an article? Please log in or register.
Vancomycin-associated hemorrhagic occlusive retinal vasculitis: a clinical-pathophysiological analysis
Retinal Diseases
Related content
Macular DiseasesRetinal DiseasesFurther Publications
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial
JAMA Ophthalmol
Aref AA, Scott IU, VanVeldhuisen PC, King J, Ip MS, Blodi BA, Oden NL, Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group.
doi: 10.1001/jamaophthalmol.2021.4395
COMMENTED
Macular DiseasesRetinal Diseases
Risk of inflammation, retinal vasculitis and retinal occlusion-related events with brolucizumab: post-hoc review of HAWK and HARRIER
★ 2
Recommended by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Ophthalmology
Monés J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, Holz FG, Korobelnik JF, Kim IK, Pruente C, Murray TG, Heier JS
doi: 10.1016/j.ophtha.2020.11.011
Retinal Diseases
Real-Life Clinical Effectiveness of Razumab® (the World's First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT Study
Ophthalmologica.
Sharma S, Khan MA, Chaturvedi A; RE-ENACT Study Investigators Group
doi: 10.1159/000488602.
Macular DiseasesRetinal Diseases
Detailed Clinical Phenotype and Molecular Genetic Findings in CLN3-Associated Isolated Retinal Degeneration
JAMA Ophthalmol.
Ku CA, Hull S, Arno G, Vincent A, Carss K, Kayton R, Weeks D, Anderson GW, Geraets R, Parker C, Pearce DA, Michaelides M, MacLaren RE, Robson AG, Holder GE, Heon E, Raymond FL, Moore AT, Webster AR, Pennesi ME
doi: 10.1001/
Retinal Diseases
The association of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio with retinal vein occlusion: a systematic review and meta-analysis
Acta Ophthalmol
Liu Z, Perry LA, Penny-Dimri JC, Raveendran D, Hu ML, Arslan J, Britten-Jones AC, O'Hare F, Ayton LN, Edwards TL
doi: 10.1111/aos.14955
Retinal Diseases
Different Factors Associated with 2-Year Outcomes in Patients with Branch versus Central Retinal Vein Occlusion Treated with Ranibizumab
Ophthalmology.
Sophie R, Wang PW, Channa R, Quezada-Ruiz C, Clark A,
Campochiaro PA
doi: 10.1016/j.ophtha.2019.07.018.
Macular DiseasesRetinal Diseases
Risk factors of recurrence of macular oedema associated with branch retinal vein occlusion after intravitreal bevacizumab injection
Br J Ophthalmol.
Yoo JH, Ahn J, Oh J, Cha J, Kim SW
doi: 10.1136/
COMMENTED
Macular Diseases
Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial
JAMA Ophthalmol.
Hykin P, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Ramu J, Hounsome B, Yang Y, Harding SP, Lotery A, Chakravarthy U, Sivaprasad S, LEAVO Study Group.
doi: 10.1001/
Retinal Diseases
Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion
JAMA Ophthalmol.
Babiuch AS, Han M, Conti FF, Wai K, Silva FQ, Singh RP
doi: 10.1001/jamaophthalmol.